Literature DB >> 11180398

Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts.

F Debiais1, J Lemonnier, E Hay, P Delannoy, J Caverzasio, P J Marie.   

Abstract

Fibroblast growth factors (FGFs) are important factors regulating osteogenesis. However, the early mechanisms and signaling pathways involved in FGF actions in osteoblasts are unknown. We investigated the effects of FGF-2 on cell-cell adhesion and cadherin expression and the underlying signaling pathways in immortalized human neonatal calvaria (IHNC) cells. These cells express E- and N-cadherins, as shown by immunocytochemical and Western blot analyses. rhFGF-2 increased cell-cell adhesion at 24-72 h, as measured in a cell aggregation assay, and this effect was blocked by specific neutralizing anti-N-cadherin, but not anti-E-cadherin antibodies. Accordingly, ELISA and Western blot analyses showed that rhFGF-2 (10-100 ng/ml) dose dependently increased N-cadherin but not E-cadherin protein levels. RT-PCR analysis showed that rhFGF-2 transiently increased N-cadherin mRNA levels in IHNC cells. The RNA polymerase II inhibitor 5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole prevented the rhFGF-2-induced up-regulation of N-cadherin mRNA, suggesting that transcription is necessary for this effect. Analysis of signaling molecules showed evidence that PLCgamma-PKC, Src, Erk 1/2 and p38 MAPK pathways are activated by rhFGF-2 in IHNC cells. The selective PKC inhibitors calphostin C, Ro-31-8220, Gö6976 and Gö6983 abrogated the stimulatory effect of rhFGF-2 on N-cadherin mRNA levels. The src-family tyrosine kinase inhibitor PP1 also blocked rhFGF-2-promoted N-cadherin expression. In contrast, the p38 MAP kinase inhibitor SB 203580 or the MEK inhibitor PD98059 had no effect on rhFGF-2-induced N-cadherin mRNA levels. Our data indicate that FGF-2 increases N-cadherin expression and function in human calvaria osteoblasts via activation of PKC and src-kinase pathways. This study identifies N-cadherin as a previously unrecognized target gene for FGF-2 signaling pathway that regulates cell-cell adhesion in human osteoblasts. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180398     DOI: 10.1002/1097-4644(20010401)81:1<68::aid-jcb1024>3.0.co;2-s

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

1.  A common variant in fibroblast growth factor binding protein 1 (FGFBP1) is associated with bone mineral density and influences gene expression in vitro.

Authors:  Nicole Hoppman; John C McLenithan; Daniel J McBride; Haiqing Shen; Jan Bruder; Richard L Bauer; John R Shaffer; Jie Liu; Elizabeth A Streeten; Alan R Shuldiner; Candace M Kammerer; Braxton D Mitchell
Journal:  Bone       Date:  2010-05-05       Impact factor: 4.398

Review 2.  Cadherin-mediated cell-cell adhesion and signaling in the skeleton.

Authors:  Pierre J Marie; Eric Haÿ; Dominique Modrowski; Leila Revollo; Gabriel Mbalaviele; Roberto Civitelli
Journal:  Calcif Tissue Int       Date:  2013-05-09       Impact factor: 4.333

3.  Bone morphogenetic protein is required for fibroblast growth factor 2-dependent later-stage osteoblastic differentiation in cranial suture cells.

Authors:  Taoran Jiang; Shengfang Ge; Yoong Hoon Shim; Ce Zhang; Dejun Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Enhanced cell-cell contact stability and decreased N-cadherin-mediated migration upon fibroblast growth factor receptor-N-cadherin cross talk.

Authors:  Thao Nguyen; Laurence Duchesne; Gautham Hari Narayana Sankara Narayana; Nicole Boggetto; David D Fernig; Chandrashekhar Uttamrao Murade; Benoit Ladoux; René-Marc Mège
Journal:  Oncogene       Date:  2019-07-16       Impact factor: 9.867

5.  FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.

Authors:  Ai Kyono; Nanthawan Avishai; Zhufeng Ouyang; Gary E Landreth; Shunichi Murakami
Journal:  J Bone Miner Metab       Date:  2011-06-17       Impact factor: 2.626

Review 6.  Research advances in Apert syndrome.

Authors:  Satrupa Das; Anjana Munshi
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-25

7.  Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

Authors:  Y-C Lee; C-F Huang; M Murshed; K Chu; J C Araujo; X Ye; B deCrombrugghe; L-Y Yu-Lee; G E Gallick; S-H Lin
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

8.  Unique modulation of cadherin expression pattern during posterior frontal cranial suture development and closure.

Authors:  David E Sahar; Björn Behr; Kenton D Fong; Michael T Longaker; Natalina Quarto
Journal:  Cells Tissues Organs       Date:  2009-12-24       Impact factor: 2.481

9.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

10.  Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.

Authors:  Shunichi Murakami; Gener Balmes; Sandra McKinney; Zhaoping Zhang; David Givol; Benoit de Crombrugghe
Journal:  Genes Dev       Date:  2004-02-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.